Other languages Femasys Inc.

Equities

FEMY

US31447E1055

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-26 EDT			5-day change	1st Jan Change
1.04 ^USD	-4.59%		+8.90%	+6.67%

06-20	Femasys Secures CE Mark Approvals for Four Women's Health Products; Shares Up Over 14%	MT
05-09	Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Femasys Secures CE Mark Approvals for Four Women's Health Products; Shares Up Over 14%	06-20
Femasys Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28
Femasys Inc. Announces Positive Topline Data from Pivotal Trial for Its Fda-Cleared Femaseed®? for the Treatment of Infertility	03-20
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution	03-06
Femasys Inc. Appoints Richard Spector as Chief Commercial Officer	02-06
Femasys Begins Patient Enrollment for Permanent Birth Control Candidate Trial	01-26
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center, A Hub for Innovation and Groundbreaking Research in Health Care for Women	01-26
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At University of Utah	01-23
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine	12-15
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer	11-30
Femasys Inc. Completes Enrollment of Femaseed Pivotal Trial in Support of Commercial Launch	11-29
Femasys Inc. Appoints Joshua Silverman as Director	11-21
Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
Femasys Inc. Successfully Completes the Stage 2 European Union (EU) Medical Device Regulation	23-10-26
Top Premarket Decliners	23-10-04
Top Midday Gainers	23-09-29
Top Midday Decliners	23-09-27
Femasys Activates Enrollment in Trial of FemBloc Birth Control Candidate	23-09-27
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate	23-09-27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Femasys Inc.

Equities

FEMY

US31447E1055

Other languages

Filters